公开(公告)号：US20070010560A1

公开(公告)日：2007-01-11

申请号：US10564185

申请日：2004-06-15

Applicant: Hans-Peter Buchstaller ,  Dirk Finsinger ,  Matthias Wiesner ,  Lars Burgdorf ,  Chriatiane Amendt ,  Matthias Grell ,  Chirstian Sirrenberg ,  Frank Zenke

Inventor： Hans-Peter Buchstaller ,  Dirk Finsinger ,  Matthias Wiesner ,  Lars Burgdorf ,  Chriatiane Amendt ,  Matthias Grell ,  Chirstian Sirrenberg ,  Frank Zenke

IPC: A61K31/4439 ,  A61K31/4184 ,  C07D403/02 ,  C07D235/28

CPC classification number: C07D401/12

Abstract: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula I or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase pathways, preferably by the raf kinase pathway, especially cancers, [FORMULA]

Abstract translation: 本发明涉及式I的苯并咪唑衍生物，式I化合物作为一种或多种激酶抑制剂的用途，式I化合物用于制备药物组合物和治疗方法的用途，其包括给药 所述药物组合物对患者而言。 因此，式I化合物或其药学上可接受的盐被用于治疗由一种或多种激酶途径介导的疾病，优选地通过raf激酶途径，特别是癌症。[公式]

公开(公告)号：US20060264419A1

公开(公告)日：2006-11-23

申请号：US10552065

申请日：2004-03-08

Applicant: Kai Schiemann ,  Karl-August Ackermann ,  Michael Arlt ,  Dirk Finsinger ,  Christoph Van Amsterdam ,  Gerd Bartoszyk ,  Christoph Seyfried ,  Oliver Schadt

Inventor： Kai Schiemann ,  Karl-August Ackermann ,  Michael Arlt ,  Dirk Finsinger ,  Christoph Van Amsterdam ,  Gerd Bartoszyk ,  Christoph Seyfried ,  Oliver Schadt

IPC: A61K31/551 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/416

CPC classification number: C07D231/12 ,  A61K31/415 ,  C07D231/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/06 ,  C07D409/10 ,  C07D413/12 ,  C07D451/06 ,  C07D453/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D491/08

Abstract: The compounds of the formula (I) and salts and solvates thereof, in which X, R1, R2, R3, R4 and R5 have the meanings indicated in Claim (1), are suitable as ligands of 5 HT receptors.

Abstract translation: 式（I）化合物及其盐和溶剂合物，其中X，R 1，R 2，R 3，R 3， SUP> 4和R 5具有权利要求（1）所示的含义，适合作为5HT受体的配体。

公开(公告)号：US06280760B1

公开(公告)日：2001-08-28

申请号：US09423347

申请日：1999-11-22

Applicant: Jorg Meyer ,  Alfred Jonczyk ,  Berthold Nies ,  Horst Kessler ,  Dirk Finsinger ,  Martin Kantlehner

Inventor： Jorg Meyer ,  Alfred Jonczyk ,  Berthold Nies ,  Horst Kessler ,  Dirk Finsinger ,  Martin Kantlehner

IPC: A61L2700

CPC classification number: C12N5/0068 ,  A61K35/12 ,  A61L27/34 ,  C12N5/0654 ,  C12N2533/50 ,  C08L89/00

Abstract: The invention describes the possibility of the biofunctionalization of biomaterials, in particular implants, by their made-to-measure coating with synthesized cell- or tissue-selective RGD peptides which in vitro stimulate the adhesion of mainly those cell species which in each case are intended to accomplish the tissue integration of the appropriate biomaterial.

Abstract translation: 本发明描述了通过其合成的细胞或组织选择性RGD肽的生物材料（特别是植入物）的生物功能化生物功能化的可能性，所述细胞或组织选择性RGD肽体外刺激主要在每种情况下被预期的那些细胞种类的粘附 完成适当生物材料的组织整合。

公开(公告)号：US07915416B2

公开(公告)日：2011-03-29

申请号：US11631185

申请日：2005-06-03

Applicant: Kai Schiemann ,  David Bruge ,  Hans-Peter Buchstaller ,  Dirk Finsinger ,  Wolfgang Staehle ,  Christiane Amendt ,  Ulrich Emde ,  Frank Zenke

Inventor： Kai Schiemann ,  David Bruge ,  Hans-Peter Buchstaller ,  Dirk Finsinger ,  Wolfgang Staehle ,  Christiane Amendt ,  Ulrich Emde ,  Frank Zenke

IPC: C07D215/38

CPC classification number: C07D491/04

Abstract: Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.

Abstract translation: 公开了式（I）的化合物，其中W，R，R 1，R 2，R 3，R 4，R 5，R 6和R 7具有权利要求1中所示的含义。所述化合物可用于治疗肿瘤， 。

公开(公告)号：US07842695B2

公开(公告)日：2010-11-30

申请号：US10552064

申请日：2004-03-10

Applicant: Oliver Schadt ,  Michael Arlt ,  Dirk Finsinger ,  Kai Schiemann ,  Christoph Van Amsterdam ,  Gerd Bartoszyk ,  Christoph Seyfried

Inventor： Oliver Schadt ,  Michael Arlt ,  Dirk Finsinger ,  Kai Schiemann ,  Christoph Van Amsterdam ,  Gerd Bartoszyk ,  Christoph Seyfried

IPC: A61K31/497 ,  A61K31/435 ,  A01N43/40 ,  C07D403/00 ,  C07D405/00 ,  C07D409/00

CPC classification number: C07D231/12 ,  C07D231/40 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/10 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: Compounds of formula (I) and salts thereof, in which the following definitions apply: X is N or CH; R1 is H, A, Hal, (CH2)nHet, (CH2)nAr, C3-7-cycloalkyl, CF3, NO2, CN, C(NH)(OH), or OCF3; R2 is (CH2)nHet, (CH2)nAr, or C3-7-cycloalkyl, or CF3; R3 and R4 denote H or an organic radical. Compounds of formula (I) are useful as ligands of 5-HT receptors and useful in the treatment of disorders such as anxiety, depression, obsessive-compulsive disorder and pain.

Abstract translation: 式（I）化合物及其盐，其中适用以下定义：X为N或CH; R1是H，A，Hal，（CH2）nHet，（CH2）nAr，C3-7-环烷基，CF3，NO2，CN，C（NH）（OH）或OCF3; R2是（CH2）nHet，（CH2）nAr或C3-7-环烷基或CF3; R3和R4表示H或有机基团。 式（I）化合物可用作5-HT受体的配体，可用于治疗焦虑，抑郁，强迫症和疼痛等疾病。

公开(公告)号：US20100022579A1

公开(公告)日：2010-01-28

申请号：US12532002

申请日：2008-02-21

Applicant: Kai Schiemann ,  Dirk Finsinger ,  Christiane Amendt ,  Frank Zenke

Inventor： Kai Schiemann ,  Dirk Finsinger ,  Christiane Amendt ,  Frank Zenke

IPC: A61K31/436 ,  C07D491/052 ,  A61P35/00

CPC classification number: C07D491/04

Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.

Abstract translation: 式（I）的化合物，其中R 1，R 2，R 3，R 4，R 5，X，Y，W，Q 1，Q 2，Z，s和m具有权利要求1所示的含义， 用于治疗肿瘤。

公开(公告)号：US20090298885A1

公开(公告)日：2009-12-03

申请号：US12488191

申请日：2009-06-19

Applicant: Hans-Peter Buchstaller ,  Matthias Wiesner ,  Oliver Schadt ,  Christiane Amendt ,  Frank Zenke ,  Christian Sirrenberg ,  Matthias Grell ,  Dirk Finsinger

Inventor： Hans-Peter Buchstaller ,  Matthias Wiesner ,  Oliver Schadt ,  Christiane Amendt ,  Frank Zenke ,  Christian Sirrenberg ,  Matthias Grell ,  Dirk Finsinger

IPC: A61K31/4439 ,  A61K31/4412 ,  C07D213/78 ,  C07D413/12 ,  C07D417/00

CPC classification number: C07D213/68 ,  A61K31/44 ,  A61K31/4439 ,  A61K45/00 ,  C07D213/75 ,  C07D213/79 ,  C07D213/81 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Abstract translation: 本发明涉及式（I）的亚甲基脲衍生物，式（I）化合物作为raf-激酶抑制剂的用途，式（I）化合物用于制备药物组合物和 包括将所述药物组合物施用于患者。

公开(公告)号：US20090253688A1

公开(公告)日：2009-10-08

申请号：US10590664

申请日：2005-02-14

Applicant: Hans-Peter Buchstaller ,  Dirk Finsinger ,  Frank Stieber ,  Matthias Wiesner ,  Christiane Amendt ,  Christian Sirrenberg ,  Frank Zenke ,  Matthias Grell

Inventor： Hans-Peter Buchstaller ,  Dirk Finsinger ,  Frank Stieber ,  Matthias Wiesner ,  Christiane Amendt ,  Christian Sirrenberg ,  Frank Zenke ,  Matthias Grell

IPC: A61K31/541 ,  C07D213/68 ,  A61K31/4409 ,  A61K31/5377 ,  C07D413/12 ,  C07D417/12 ,  A61P35/00

CPC classification number: C07D213/68 ,  C07D213/81 ,  C07D401/12

Abstract: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Abstract translation: 本发明涉及式I的氨基脲衍生物，式I化合物作为一种或多种激酶的抑制剂的用途，式I化合物在制备药物组合物中的用途及其治疗方法，其包括施用 所述药物组合物对患者而言。

公开(公告)号：US07598274B2

公开(公告)日：2009-10-06

申请号：US10579825

申请日：2004-10-26

Applicant: Dirk Finsinger ,  Hans-Peter Buchstaller ,  Lars Burgdorf ,  Matthias Wiesner ,  Christiane Amendt ,  Matthias Grell ,  Christian Sirrenberg ,  Frank Zenke

Inventor： Dirk Finsinger ,  Hans-Peter Buchstaller ,  Lars Burgdorf ,  Matthias Wiesner ,  Christiane Amendt ,  Matthias Grell ,  Christian Sirrenberg ,  Frank Zenke

IPC: A61K31/4439 ,  C07D401/02

CPC classification number: C07D207/337 ,  C07D401/12

Abstract: Compounds of the formula (I), in which X, Y, Z and Ar have the meanings indicated in claim 1, are inhibitors of Raf kinase and can be employed, inter alia, for the treatment of tumours

Abstract translation: 其中X，Y，Z和Ar具有权利要求1所述含义的式（I）化合物是Raf激酶的抑制剂，并且可以用于治疗肿瘤

公开(公告)号：US07589112B2

公开(公告)日：2009-09-15

申请号：US10532574

申请日：2003-10-08

Applicant: Hans-Peter Buchstaller ,  Matthias Wiesner ,  Oliver Schadt ,  Christiane Amendt ,  Frank Zenke ,  Christian Sirrenberg ,  Matthias Grell ,  Dirk Finsinger

Inventor： Hans-Peter Buchstaller ,  Matthias Wiesner ,  Oliver Schadt ,  Christiane Amendt ,  Frank Zenke ,  Christian Sirrenberg ,  Matthias Grell ,  Dirk Finsinger

IPC: A61K31/4412 ,  C07D213/68

CPC classification number: C07D213/68 ,  A61K31/44 ,  A61K31/4439 ,  A61K45/00 ,  C07D213/75 ,  C07D213/79 ,  C07D213/81 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Abstract translation: 本发明涉及式（I）的亚甲基脲衍生物，式（I）化合物作为raf-激酶抑制剂的用途，式（I）化合物用于制备药物组合物和 包括将所述药物组合物施用于患者。